Anixa Biosciences (ANIX)

Executive Summary

Anixa Biosciences is a clinical-stage biotechnology company leveraging a proprietary 'retired proteins' approach to develop immunotherapies for solid tumors. The company's dual-platform pipeline includes a CER-T cell therapy targeting the follicle-stimulating hormone receptor (FSHR) for ovarian cancer (Phase 1, NCT05316129) and a vaccine targeting α-lactalbumin for triple-negative breast cancer (Phase 1, NCT04674306). By targeting antigens that are normally expressed only during specific life stages (e.g., lactation) but are re-expressed in tumors, Anixa's therapies aim to provide highly targeted cancer treatment with reduced toxicity. The company is publicly traded (NASDAQ: ANIX) with a market cap of approximately $100 million. While still in early clinical development, Anixa's novel mechanism and focus on underserved cancers like ovarian and triple-negative breast cancer offer significant potential if clinical data prove positive.

Upcoming Catalysts (preview)

• H2 2026Phase 1 Data Readout for CER-T in Ovarian Cancer (NCT05316129)40% success
• Q2 2026Phase 1 Data Readout for α-Lactalbumin Vaccine in TNBC (NCT04674306)50% success
• TBDPotential Partnership or Grant Announcement30% success